Key stats
About Franklin Genomic Advancements ETF
Expense ratio
0.50%
Home page
Inception date
Feb 25, 2020
HELX invests in global companies benefitting from the advancements of genomic-based research techniques and technologies that are designed to extend or enhance the quality of life. The fund advisor uses fundamental research to identify and select stocks they feel best positioned to capitalize on such genomic advancements. Companies may include those that research, develop, produce or manufacture bionic devices, molecular medicine, pharmaceuticals and agricultural applications. HELX is one of the first three thematic funds to launch from Franklin Templeton.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Commercial Services
Stocks98.73%
Health Technology76.82%
Commercial Services12.07%
Technology Services3.47%
Health Services3.28%
Process Industries2.77%
Finance0.32%
Bonds, Cash & Other1.27%
Cash1.27%
Stock breakdown by region
North America92.54%
Europe4.41%
Asia3.05%
Latin America0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history